argenx scales its global rare-disease supply chain with Shipsy’s AI-native TMS

argenx — a global biotech with ≈USD 4.15B in net sales, 1,599 employees, and presence in 30+ countries — achieved >95% SLA compliance, real-time cold-chain temperature alerts, and 50–70% manual-effort reduction after deploying Shipsy’s AI-native TMS across its rare-disease therapeutics supply chain. Integrated directly with Oracle ERP and Veeva QMS, the platform unified parcel, pallet, and batch flows across carriers and CDMOs into a single source of truth with 95% batch instrumentation.

Customer: argenx — global biotech, rare-disease therapeutics. Industry: Pharma (biotech). Region: Global (30+ countries). Shipsy modules deployed: TMS, Control Tower, Cold-chain visibility, 3PL orchestration, Oracle ERP + Veeva QMS integrations, Automated finance. Headline metric: >95% SLA compliance, 50–70% manual effort reduction.

The Challenge

Rare-disease therapeutics are a supply chain edge case. Small patient populations, strict temperature regimes, multiple CDMOs, multiple carriers, multiple regulatory regimes — and zero tolerance for a missed batch reaching a patient.

argenx was scaling that supply chain globally without a unified visibility layer. Shipments could miss pre-defined gates without anyone knowing until it was too late; monitoring was reactive, not proactive. Carrier and tracking data was fragmented — multiple carriers, multiple non-standardized tracking formats, no single pane of glass. Cold-chain exposure was a material risk: no automated temperature alerts, no central excursion control, which in a biologics portfolio translates directly to batch integrity and patient safety concerns. Finance added friction at the other end — limited visibility into rate cards, transport costing, and invoice reconciliation, with a manual overhead that scaled linearly with volume.

argenx needed a system that could act, not just record — one that could scale with a growing rare-disease portfolio without a proportional headcount increase.

The Solution

Shipsy deployed an AI-native TMS engineered for regulated pharma flows, anchored on four capabilities.

Real-time visibility and SLA gates. A single source of truth for parcel, pallet, and batch flows across argenx, its carriers, and its CDMOs. Pre-defined SLA gates are monitored in real time; missed gates trigger immediate surfacing. This replaced the fragmented, reactive monitoring model with a unified operational picture. Learn more in our pharma CDMO shipment visibility benchmark.

AI-native orchestration and predictive alerts. The TMS “acts, learns, and transforms.” Predictive alerts surface risk upstream — temperature excursions, transit delays, carrier anomalies — with automated remediation workflows rather than manual investigation. This is where the platform moves from system of record to system of action.

3PL orchestration with transport-order workflows. Slot booking, transport-order workflows, and collaboration primitives let argenx, its forwarders, and its CDMOs coordinate on the same platform. What used to be email-and-spreadsheet handoffs now live as structured workflows with audit trails.

Integration with Oracle ERP and Veeva QMS. The two non-negotiable integration points for a regulated biotech. Shipsy plugs directly into Oracle for the transactional backbone and Veeva QMS for the quality-management layer. Batch data, quality events, and transport data stay synchronized across systems.

Automated finance. Invoice reconciliation, rate-card enforcement, and cost analytics run as automated workflows rather than a manual finance overhead. Rate-card mismatches get flagged at ingestion; reconciliation runs on a schedule rather than on a human.

The Outcome

The deployment delivered step-change outcomes across compliance, operations, and economics:

For a biotech where every batch matters and every missed gate is a potential patient-safety event, 95%+ SLA compliance and near-complete batch instrumentation are structural capabilities, not operational niceties. They underwrite the business’s ability to scale rare-disease therapeutics globally with confidence.

The finance side is quieter but equally important: with rate cards enforced automatically and invoices reconciled on schedule, the compounding manual-work tax that scales with volume has been structurally eliminated.

What’s Next

argenx is extending the platform into deeper cold-chain intelligence (predictive excursion modelling), broader CDMO coverage as the network expands, and evaluation of AgentFleet — specifically Nexa for settlement automation on the forwarder billing stream. The strategic goal: make the supply chain a scaling-enabling asset rather than a scaling constraint.